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Heparin cofactor II (HCII) is presumed to be a physi-
ological inhibitor of the serine proteinase thrombin. The
reaction between HCII and thrombin is quite unique,
because it involves an unusual HCII-reactive site loop
sequence of Leu444-Ser445, requires the presence of gly-
cosaminoglycans for optimal activity and involves a pro-
tein-protein interaction besides the reactive site loop-
active site interaction characteristic of serine
proteinase inhibitor-serine proteinase pairs. Two muta-
tions at a unique HCII residue, Arg2003 Ala or Glu, were
generated by site-directed mutagenesis. The mutations
did not alter either HCII binding to heparin-Sepharose
or HCII inhibition of thrombin in the presence of hepa-
rin or dermatan sulfate, suggesting that Arg200 is not
part of the glycosaminoglycan binding site of HCII. In
the absence of glycosaminoglycan, there was a signifi-
cant increase in a-thrombin inhibition by the Arg200
mutants as compared with wild type recombinant HCII
(wt-rHCII), whereas inhibition rates with chymotrypsin
were identical. Inhibition of gT-thrombin, which lacks
anion-binding exosite 1 ((ABE-1), the region of a-throm-
bin that interacts with the acidic domain of HCII), was
significantly reduced compared with a-thrombin, but
the reduction was more dramatic for the Arg200-rHCII
mutants. Hirugen, which binds to ABE-1 of a-thrombin,
also diminished inhibition of a-thrombin by the Arg200-
rHCII mutants to nearly wt-rHCII levels. Both Arg200-
rHCII mutants had significantly increased ka values as
compared with wt-rHCII, whereas the kd rates were un-
changed. Collectively, these results suggest that the im-
proved inhibitory activity of the Arg200-rHCII mutants is
mediated by enhanced interactions between the acidic
domain and ABE-1, resulting in an increased HCII-
thrombin association rate.
Serine proteinase inhibitors (serpins)1 are a superfamily of
proteins whose primary function is to regulate the proteolytic
activity of serine proteinases involved in such processes as
coagulation, fibrinolysis, complement activation, inflamma-
tion, and tumor metastasis (Refs. 1 and 2 and reviewed in Ref.
3). Heparin cofactor II (HCII) belongs to a subfamily of serpins
whose activity is greatly accelerated upon binding to glycos-
aminoglycans, such as heparin, heparan sulfate, and derma-
tan sulfate (4, 5). In vivo, glycosaminoglycan-containing pro-
teoglycans found on cell surfaces and in extracellular matrix
serve to accelerate this reaction (6–8). The physiological target
of HCII is presumed to be thrombin, a pluripotent coagulation
proteinase that participates in inflammation and wound heal-
ing processes based on its chemotactic, mitogenic, and cyto-
kine-like action on vascular smooth muscle cells, monocytes,
and fibroblasts (9–12). Thrombin activity generated during
blood coagulation is regulated primarily by antithrombin, a
heparin-binding serpin that inhibits most coagulation protein-
ases. However, extravascular thrombin activity associated
with inflammation and wound healing processes is thought to
be regulated by HCII, which exhibits remarkable specificity for
thrombin (13, 14).
HCII possesses several characteristics for thrombin specific-
ity that render it unique among heparin-binding serpins. HCII
is the only heparin-binding serpin that binds dermatan sulfate
to accelerate thrombin inhibition (15). The heparin and derma-
tan sulfate binding sites, which are distinct but overlapping,
are localized primarily in the D-helix region (16–19). HCII is
also unique because it has Leu444 at the P1 position, whereas
most thrombin-inhibiting serpins (like antithrombin and pro-
tein C inhibitor) and typical thrombin substrates contain an
Arg at the P1 site (20, 21). The P1 residue, which is located on
an exposed loop that interacts with the active site of the pro-
teinase, determines in large part the proteinase specificity of
the serpin (for a review, see Ref. 3). The presence of a P1 Leu in
HCII enables it to inhibit chymotrypsin, a nonphysiological
target, more rapidly than thrombin in the absence of glycos-
aminoglycans (22). HCII with an Arg substituted for the P1
Leu no longer inhibits chymotrypsin (23). Interestingly, this
mutant has an increased thrombin inhibition rate in the ab-
sence of glycosaminoglycans, but is also proteolytically inacti-
vated by thrombin in the presence of heparin (23, 24).
Although HCII is ;30% identical in primary structure to
antithrombin and other serpins (25), it has an unusual amino-
terminal extension of approximately 80 residues (26, 27). The
amino terminus contains a tandem repeat of two acidic
stretches that are somewhat homologous to the carboxyl ter-
minus of the leech thrombin inhibitor, hirudin (28). The acidic
domains of both HCII and hirudin bind to anion-binding ex-
osite-1 (ABE-1) of thrombin (29). The acidic domain of HCII is
also thought to bind intramolecularly to the D-helix, the gly-
cosaminoglycan binding site on HCII. Binding of glycosamin-
oglycans to the D-helix is thought to displace the acidic domain
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and promote its interaction with ABE-1 of thrombin (30, 31).
The acidic domain interaction with ABE-1 appears to be the
driving force for the rapid inhibition of thrombin by HCII in the
presence of glycosaminoglycans and compensates for the unfa-
vorable P1 Leu residue (19, 30, 32).
We are studying HCII to better understand the role of spe-
cific amino acid residues in this unique thrombin inhibition
reaction. A comparison of serpin sequences shows that HCII is
the only heparin-binding serpin with a basic residue at Arg200
(2). Arg200 of HCII is in strand 2 of b sheet A, adjacent to the
dermatan sulfate-binding region of the D-helix; thus it may be
poised to play a unique role in regulating HCII activity. In this
study, we have found that Arg200 promotes the interaction of
the acidic domain with HCII in the absence of glycosaminogly-
cans, but is not involved in glycosaminoglycan binding. We
propose that the function of Arg200 is to keep HCII essentially
“inactive” when it is circulating in the blood stream unbound to
glycosaminoglycans.
EXPERIMENTAL PROCEDURES
Generation and Expression of R200A-rHCII and R200E-rHCII—Hu-
man wild type recombinant HCII (wt-rHCII) (cDNA kindly provided by
Dr. Douglas M. Tollefsen, Washington University School of Medicine,
St. Louis, MO) was previously expressed in the baculovirus expression
system and characterized (33). To generate R200A-rHCII and R200E-
rHCII, site-directed mutagenesis was performed by the method of
Kunkel on full-length human HCII cDNA subcloned via flanking EcoRI
sites into the pBluescript SK1 mutagenesis and cloning vector (Strat-
agene) (34). A degenerate oligonucleotide was used to introduce two
point mutations in the HCII cDNA (683CGG 3 GCG or GAG), which
caused substitutions of Ala or Glu, respectively, at residue Arg200. The
mutations were identified by DNA sequencing (Sequenase® Version
2.0, U. S. Biochemical Corp.), and positive clones were sequenced in full
to verify the absence of erroneously introduced mutations. Subcloning
into baculoviral transfer vector pVL1392 (PharMingen) and cotransfec-
tion with linearized BaculoGold™ (PharMingen) Autographica califor-
nica nuclear polyhedrosis virus in Spodoptera frugiperda (Sf9, Invitro-
gen) insect cells was performed as described previously (33). The
infectious medium was collected 4 days post-transfection and was fur-
ther amplified in fresh Sf9 cells. Production of rHCII was verified by
immunoblot analysis of whole cell lysates from infected cells. Sf9 cells
were maintained in spinner flasks in Grace’s medium (JRH Scientific)
supplemented with 10% fetal bovine serum (HyClone), 0.3 g/liter L-
glutamine (Life Technologies, Inc.), and 50 mg/ml gentamicin (Life
Technologies, Inc.).
Protein Expression and Purification—High-Five™ insect cells (In-
vitrogen) grown at 27 °C in serum free ExCell 401™ medium with
L-glutamine (JRH Scientific) were used to express rHCII. Two T150
flasks of High-Five™ cells were infected with viral stock (150 ml/flask),
and the cell supernatant was collected after 2 days and centrifuged at
350 3 g for 5 min to remove cell debris. The medium was diluted with
an equal volume of HPN buffer, pH 6.5 (20 mM HEPES (Boehringer
Mannheim), 0.1% polyethylene glycol 8000 (Sigma), 0.05% NaN3) and
batch-adsorbed with 0.5 ml of heparin-Sepharose beads (Pharmacia
Biotech Inc.) for 1 h at 4 °C. rHCII was eluted from the heparin-
Sepharose with 0.5 M NaCl in HPN buffer, pH 7.4, after two washes in
75 mM NaCl in HPN, pH 6.5, buffer. The heparin-Sepharose eluate was
diluted in HPN buffer to a final concentration of 50 mM NaCl, pH 7.8,
and batch-adsorbed with 0.5 ml of Q-Sepharose (Sigma) for 1 h at 4 °C.
After two washes in 50 mM NaCl, the protein was eluted with 0.5 M
NaCl in HPN, pH 7.8, buffer, aliquoted, and stored at 270 °C.
Quantification of rHCII—A direct enzyme-linked immunosorbent
assay using a mouse anti-HCII monoclonal antibody and a goat IgG-
conjugated to alkaline phosphatase (Sigma) was used as described
previously to measure rHCII concentrations (33). Human plasma HCII,
purified as described previously (35), was used for the standard curve.
Assays were performed in 96-well microtiter plates and color develop-
ment was monitored at 405 nm on a Vmax microplate reader (Molecular
Devices).
Heparin-Sepharose Chromatography—The relative affinity of wt-rH-
CII and the R200-rHCII mutants for immobilized heparin was deter-
mined by fast protein liquid chromatography using a Pharmacia Bio-
tech Inc. system and a 1-ml heparin-Sepharose column. The samples
were dialyzed into 20 mM HEPES, 50 mM NaCl, 0.1% polyethylene
glycol, pH 7.4, loaded onto the column with dialysis buffer, and eluted
with a linear 1.0 ml/min salt gradient of 50 mM to 0.5 M NaCl. 1.0 mg of
recombinant HCII was loaded, and 20 3 1-ml fractions were collected.
The fractions were analyzed by thrombin inhibition assays in the pres-
ence of 10 mg/ml heparin, as described below.
Proteinase Inhibition Assays—Human a-thrombin was isolated and
prepared as described previously (36), and bovine chymotrypsin was
purchased from Sigma. gT-Thrombin was prepared by limited proteol-
ysis of plasma-derived a-thrombin with L-1-tosylamido-2-phenylethyl
chloromethyl ketone-treated trypsin (Cooper Biomedical) [(37) as mod-
ified in (32)]. The activity of gT-thrombin was then verified by chromo-
genic substrate cleavage and fibrin clotting assays. Chromogenic sub-
strates were tosyl-Gly-Pro-Arg-r-nitroanilide (150 mM; Boehringer
Mannheim) for thrombin and N-succinyl-Ala-Ala-Pro-Phe-r-nitroani-
lide (500 mM; Sigma) for chymotrypsin. Hirugen (residues 53–64) was
from Multiple Peptide Systems. A control peptide corresponding to the
reverse sequence of the HCII acidic domain (residues 47–61) was syn-
thesized on a Synergy™ peptide synthesizer (Applied Biosystems). Pro-
teinase inhibition assays for wt-rHCII and the R200-rHCII mutants
were performed in 96-well enzyme-linked immunosorbent assay plates
(previously coated with 2 mg/ml bovine serum albumin) at room tem-
perature in HNPN, pH 7.4, buffer containing 2 mg/ml bovine serum
albumin. In the absence of glycosaminoglycan, 100 nM HCII and 1 nM
thrombin were incubated together for 30–180 min in the presence of 50
mg/ml polybrene. The thrombin-HCII association time was 90 min for
assays performed in the presence of hirugen. For the heparin (Diosynth,
Oss, The Netherlands) and dermatan sulfate (Calbiochem; nitrous acid-
treated to remove contaminating heparin and heparan sulfate) tem-
plate curves, 5 nM HCII, and 0.5 nM thrombin were incubated together
for 20 s. The reactions were quenched by the addition of a chromogenic
substrate solution containing 3 mg/ml polybrene, and color develop-
ment was monitored at 405 nm on a Vmax microplate reader. Second
order inhibition rate constants (k2, M
21 min21) were measured in trip-
licate on two to four different preparations of rHCII. The rates were
obtained under pseudo-first order reaction conditions as described pre-
viously and were calculated using the equation k2 5 (2ln a)/t [I], where
a is the residual proteinase activity, t is the time, and [I] is the HCII
concentration (38).
Slow Binding Kinetics—Slow binding kinetic assays were performed
in 96-well bovine serum albumin-coated enzyme-linked immunosorbent
assay plates at room temperature in HNPN, pH 7.4, buffer containing
2 mg/ml bovine serum albumin. A low-evaporation lid coated with
anti-fogging agent (Molecular Devices) was used to minimize evapora-
tion. Chromogenic substrate was S-2266 (D-Val-Leu-Arg-r-nitroanilide;
Kabi Pharmacia). S-2266 was selected from several chromogenic sub-
strates tested because its high Km (262 mM; Ref. 39) permitted adequate
inhibition of thrombin by HCII under the experimental conditions.
Color development was monitored as described above. The reaction was
started by the addition of 0.5 nM thrombin to wells containing varying
concentrations of HCII (25–400 mM range) and 500 mM S-2266, and
readings were taken at 10-min intervals for 8 h. Data points were
excluded from the analysis when the level of substrate utilization ex-
ceeded 10%. Control assays indicated that the thrombin was stable
during the course of the experiment.
The competition between substrate and inhibitor for thrombin can be











where E, S, P, and I represent the enzyme (thrombin), substrate (D-Val-
Leu-Arg-r-nitroanilide), product (r-nitroaniline), and inhibitor (HCII),
respectively. Km and kcat are the Michaelis and catalytic constants for
the enzyme-substrate reaction, respectively, and ka and kd are the
association and dissociation rate constants for the thrombin-HCII re-
action. This kinetic scheme assumes reversible binding, which the
HCII-thrombin interaction appears to follow under the conditions es-
tablished in this assay, since vs was significant at all concentrations of
serpins. The progress curve of product formation for this mechanism is
given by Equation 1 (40),
P 5 vst 1 @~vo 2 vs!/k9#~1 2 e2k9t! (Eq. 1)
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where P is the amount of product at time t, k9 is an apparent first-order
rate constant, and vo and vs are the initial and steady-state velocities,
respectively. A plot of k9 versus inhibitor concentration (Equation 2)
yields a slope equal to k9a, the apparent association rate, and a y
intercept equal to kd (39).
k9 5 kd 1 k9a z I (Eq. 2)
The k9a is related to the true rate constant by Equation 3.
ka 5 k9a ~1 1 ~S/Km!! (Eq. 3)
vo was determined from a linear fit to the first 10 measurements of the
thrombin alone control for each row on the microplate, and this value
was then used in Equation 1. The data from the progress curves were
fitted to Equation 1 by nonlinear regression using software written for
SlideWrite. The values for k9 at each HCII concentration were then used
to determine k9a and kd by a linear fit of the data to Equation 2. The true
ka was then determined from Equation 3.
RESULTS
Generation and Expression of R200A-rHCII and R200E-
rHCII—R200A-rHCII and R200E-rHCII were engineered, ex-
pressed, and purified as described under “Experimental Proce-
dures.” The protein yield from a typical preparation was essen-
tially the same as for wt-rHCII (50–100 mg purified from two
T150 flasks). Immunoblot analysis and SDS-PAGE demon-
strated the mutants had the same electrophoretic mobility as
wt-rHCII (data not show).
Heparin-Sepharose Affinity Chromatography of wt-rHCII
and the Arg200 Mutants—Gradient salt elution from heparin-
Sepharose was performed to determine whether the mutations
altered the apparent affinity of HCII for immobilized heparin.
Since the intermolecular interactions between heparin and
HCII are thought to be primarily ionic, the concentration of
NaCl required to elute the proteins is a measure of their rela-
tive affinity (41). There were no significant differences in the
NaCl concentrations (mM) required to elute the proteins: 270 6
40 for wt-rHCII (n 5 3), 260 6 20 for R200A-rHCII (n 5 4), and
270 6 40 for R200E-rHCII (n 5 3).
Glycosaminoglycan-accelerated a-Thrombin Inhibition—The
Arg200 mutants were assayed for their ability to inhibit throm-
bin in the presence of glycosaminoglycans. Fig. 1 shows that
both HCII mutants exhibited typical bell-shaped curves for
inhibition of a-thrombin in the presence of increasing concen-
trations of heparin or dermatan sulfate. While the optimal
heparin concentration is about 2-fold higher for the Arg200
mutants (500 mg/ml) as compared with wt-rHCII (200 mg/ml)
(Fig. 1A), the second order inhibition rate constants (k2, M
21
min21) are not significantly different (see Table I). Likewise,
dermatan sulfate-accelerated thrombin inhibition was identi-
cal for wt-rHCII and the Arg200 mutants, both in terms of
optimal dermatan sulfate concentration and maximal inhibi-
tion rate (Fig. 1B and Table I).
Inhibition of a-Thrombin, gT-Thrombin, and Chymotrypsin
in the Absence of Glycosaminoglycans—wt-rHCII and the
Arg200 mutants were assayed for their ability to inhibit
a-thrombin, gT-thrombin, and chymotrypsin in the absence of
glycosaminoglycans. The second order rate constants of inhibi-
tion (k2, M
21 min21) are summarized in Table I. With a-throm-
bin, both mutants have significantly higher inhibition rates
than wt-rHCII (p , 0.05). The k2 values for R200A-rHCII and
R200E-rHCII are 3.5- and 5.6-fold higher, respectively, than
wt-rHCII. In contrast, the k2 values for wt-rHCII and the
Arg200 mutants were identical with chymotrypsin (p . 0.05),
indicating that the mutations did not alter the conformation of
the reactive site loop.
To determine whether the increased inhibitory activity of
HCII with a-thrombin is due to enhanced interactions between
the acidic domain and ABE-1, inhibition assays were per-
formed with gT-thrombin. gT-Thrombin lacks portions of
ABE-1, which have been removed by limited proteolysis with
trypsin. All three HCII variants had lower inhibition rates with
gT-thrombin as compared with a-thrombin, but the greater
decrease in activity was observed with the Arg200 mutants.
Although the k2 values of the mutants are still higher than
FIG. 1. Glycosaminoglycan-accelerated a-thrombin inhibition
by wt-rHCII and the Arg200 mutants. a-Thrombin (0.5 nM) was
incubated with 5 nM wt-rHCII (f), R200A-rHCII (Ç), or R200E-rHCII
(E) in the presence of increasing concentration of heparin (A) or der-
matan (B) sulfate. The inhibition rate constant (k2) is plotted on the y
axis versus the glycosaminoglycan concentration of the x axis. The
above curves represent the mean values of four to seven
determinations.
TABLE I
Second-order rate constants (k2 ) for proteinase inhibition
by wt-rHCII and Arg200 mutants
Inhibition rate constants (k2, M
21 min21) for wt-rHCII, R200A-rHCII,
and R200E-rHCII with a-thrombin, gT-thrombin, and chymotrypsin are
summarized below. For glycosaminoglycan-accelerated inhibition, tem-
plate curves were performed in the presence of increasing concentra-
tions of glycosaminoglycan, and the maximal inhibition rates were
taken from an average of the curves. Assays were performed as de-
scribed under “Experimental Procedures,” and values are expressed as






2GAG 2.7 6 1.1 3 104 9.5 6 3.2 3 104 a 15.4 6 3.8 3 104 a
1 Heparin 4.1 6 0.4 3 108 5.5 6 1.4 3 108 4.6 6 0.8 3 108
(200 mg/ml)b (500 mg/ml) (500 mg/ml)
1 Dermatan 1.2 6 0.2 3 109 1.3 6 0.3 3 109 1.1 6 0.2 3 109
sulfate (1000 mg/ml) (1000 mg/ml) (1000 mg/ml)
gT-Thrombin 1.4 6 0.5 3 10
4 3.3 6 1.2 3 104 3.2 6 0.9 3 104
Chymotrypsin 1.6 6 0.2 3 105 1.7 6 0.9 3 105c 1.7 6 1.0 3 105 c
a p , 0.05 compared with wt-rHCII.
b The optimal glycosaminoglycan (GAG) concentration is shown in
parentheses below the inhibition rate.
c p . 0.05 compared with wt-rHCII.
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wt-rHCII (p , 0.05), they are both now only 2.3-fold higher
than wt-rHCII (Table I).
The Effect of Hirugen on Inhibition of a-Thrombin in the
Absence of Glycosaminoglycan—To further examine the role of
ABE-1 in the enhanced activity of the Arg200 mutants, the rate
of a-thrombin inhibition in the presence of hirugen was deter-
mined. By binding directly to ABE-1, hirugen interferes with
acidic domain-ABE-1 interactions and reduces the rate of
a-thrombin inhibition by HCII (33). Increasing amounts of
hirugen resulted in a dose-dependent blockage of the HCII-
thrombin reaction, with a maximal response at 100 mM for all
three HCII proteins (data not shown). Hirugen has a greater
effect on the ability of the Arg200 mutants to inhibit a-thrombin
than it does on wt-rHCII. At 100 mM hirugen, the a-thrombin
inhibition rates (k2, M
21 min21) for R200A-rHCII and R200E-
rHCII were reduced to 2.2 6 0.8 3 104 and 2.8 6 0.6 3 104,
respectively, as compared with 1.0 6 0.4 3 104 for wt-rHCII
(Fig. 2). This effect is specific since a control peptide that was
highly negatively charged could not block the HCII-thrombin
reactions (Fig. 2).
Slow Binding Kinetics for the Inhibition of a-Thrombin—To
determine whether the enhanced activity of the mutants is due
to an increased HCII-thrombin association rate (ka) or to a
decreased HCII-thrombin dissociation rate (kd), a slow binding
kinetics assay was developed for HCII inhibition of thrombin.
In slow binding kinetics, the inhibitor and substrate compete
for binding to the proteinase. Shown in Fig. 3 are representa-
tive time courses of a-thrombin inhibition at different HCII
concentrations. Analysis of the raw data yielded a good fit to
Equation 1, typically with correlation coefficients (r2) of 0.999.
The values obtained for k9 were used to estimate ka and kd, as
described under “Experimental Procedures.” A representative
plot of k9 versus HCII concentration, shown in Fig. 4, demon-
strates the significantly increased ka of the Arg
200 mutants as
compared with wt-rHCII. The ka values (Table II) for R200A-
rHCII and R200E-rHCII are 5- and 9-fold higher, respectively,
than wt-rHCII. Interestingly, the calculated kd for all the HCII
variants are not significantly different (p . 0.05).
DISCUSSION
We initially hypothesized that Arg200 of HCII would be im-
portant for the glycosaminoglycan-mediated inhibitory activity
of HCII with thrombin because no other heparin-binding serpin
has a basic residue at the analogous position. Furthermore,
Arg200 is adjacent to the D-helix region of HCII, previously
established to be important for activity. We expected that
changing this positively charged residue to an uncharged ala-
nine or a negatively charged glutamic acid would decrease both
heparin-Sepharose affinity and glycosaminoglycan-mediated
thrombin inhibition. However, mutations at Arg200 did not
affect either heparin binding or heparin- and dermatan sulfate-
accelerated thrombin inhibition. Although slightly higher con-
centrations of heparin were required to optimally stimulate
inhibition of thrombin by the mutants, the maximal inhibition
rate was nearly identical to wt-rHCII. Mutation of critical
D-helix residues in previous studies has led to both signifi-
cantly decreased glycosaminoglycan-accelerated thrombin in-
hibition and reduced heparin-Sepharose affinity (16–18). The
FIG. 2. The effect of hirugen on the rate of a-thrombin inhibi-
tion by wt-rHCII and the Arg200 mutants. HCII (100 nM) was
incubated with 1 nM a-thrombin in the absence of hirugen (f), in the
presence of 100 mM hirugen (u), or in the presence of 100 mM control
peptide (o) for 90 min, and the residual thrombin activity was deter-
mined as described under “Experimental Procedures.” Second order
rate constants of inhibition (k2) are plotted on the y axis for each
condition tested. The above data represent the mean (6 S.D.) of two to
six determinations.
FIG. 3. Slow binding kinetics for the inhibition of a-thrombin
by wt-rHCII and the Arg200 mutants. Shown above are the progress
curves of a-thrombin inhibition by wt-rHCII (A), R200A-rHCII (B), and
R200E-rHCII (C) for a representative experiment. a-Thrombin (0.5 nM)
and 500 mM D-Val-Leu-Arg-r-nitroanilide were incubated in the absence
of inhibitor (M) or in the presence of 25 (L), 50 (E), 75 (1), 100 (Ç), 200
(v), or 400 (U) nM HCII. Chromogenic substrate hydrolysis, shown as
absorbance, is plotted on the y axis versus the reaction time (minutes)
on the x axis.
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finding that R200A-rHCII and R200E-rHCII are fully active in
the presence of both heparin and dermatan sulfate and that
their heparin-Sepharose elution profiles are nearly identical
indicates that Arg200 is not critical for glycosaminoglycan
binding.
Interestingly, the thrombin inhibition rates of R200A-rHCII
and R200E-rHCII in the absence of glycosaminoglycans were
significantly increased. The increased inhibitory activity of the
mutants appears to be caused by an enhanced interaction be-
tween the HCII acidic domain and ABE-1 of thrombin, since
inhibition rates with gT-thrombin are more significantly re-
duced for the mutants than for wt-rHCII. Furthermore, the
addition of hirugen to the HCII-thrombin reaction reduces the
activity of the mutants to almost the same level as that of
wt-rHCII. However, even with gT-thrombin or a-thrombin/
hirugen, the mutants are still more active than wt-rHCII, most
likely because the acidic domain binding site on ABE-1 is
neither totally removed in gT-thrombin nor completely blocked
by hirugen. We have shown previously that dermatan sulfate
accelerates gT-thrombin inhibition by HCII by 30-fold, indicat-
ing that the acidic domain still interacts with the remaining
portions of ABE-1 in a productive manner (32). Finally, the
identical inhibition rates of wt-rHCII and the Arg200 mutants
with chymotrypsin (which does not require either the acidic
domain of HCII or glycosaminoglycans for inhibition) indicate
that the reactive site loop has not been altered to an “activated”
conformation, further implicating a role for the acidic domain
in the increased activity of the mutants.
To determine whether the enhanced interaction between the
acidic domain of the Arg200 mutants and ABE-1 of thrombin
resulted in an increased association rate (ka) or a decreased
dissociation rate (kd), a slow binding kinetics assay, previously
used to characterize other serpin-proteinase reactions, was
adapted for HCII-thrombin. These studies revealed that the
increased inhibitory activity of the mutants is due to an in-
creased association rate (ka) with thrombin. This suggests that
the acidic domain is more involved in the initial “handshake”
between HCII and thrombin than in the stabilization of the
bimolecular serpin-proteinase complex. These results imply
that for wild type HCII, Arg200 helps to maintain acidic do-
main-HCII intramolecular interactions, thus attenuating
thrombin inhibition in the absence of glycosaminoglycans.
Previous studies have led to the hypothesis that the D-helix
is the intramolecular binding site for the acidic domain in
HCII. A study instrumental in developing this hypothesis
showed that amino-terminal truncation mutants of HCII that
are missing one (D67-rHCII) or both (D74-rHCII) acidic repeats
have greatly increased heparin-Sepharose affinity (30). A D-
helix double mutant (R184Q/K185Q-rHCII) generated by site-
directed mutagenesis was shown to have significantly de-
creased heparin-Sepharose affinity, enhanced ability to form
SDS-PAGE-stable complexes with thrombin in the absence of
glycosaminoglycans, but reduced ability to form complexes in
the presence of glycosaminoglycans (19). This study suggested
that the increased formation of R184Q/K185Q-rHCII-thrombin
complexes in the absence of glycosaminoglycans was due to a
disruption in acidic domain interactions with R184 and K185,
resulting in increased acidic domain interaction with ABE-1.
Our results imply that in the absence of glycosaminoglycan,
the presence of an Arg at residue 200 either promotes acidic
domain interactions with the D-helix of HCII or binds the
acidic domain directly. Changing Arg200 to an Ala or Glu would
alter the “equilibrium” and favor the interaction of the acidic
domain and ABE-1, resulting in increased thrombin inhibition.
These results are also consistent with the hypothesis that the
mechanism of acidic domain binding to ABE-1 is part of the
HCII-thrombin association reaction. Finally, this interaction
would further contribute to maintaining blood plasma HCII in
a conformation that would be a poor thrombin inhibitor in the
absence of glycosaminoglycans.
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